| Tracy R Woodward, MD | |
|
1133 Lincoln Ave 201, Evansville, IN 47714-1028 | |
| (812) 303-0212 | |
| (812) 759-0643 |
| Full Name | Tracy R Woodward |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 29 Years |
| Location | 1133 Lincoln Ave 201, Evansville, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508973934 | NPI | - | NPPES |
| 01056773A | Other | IN | LICENSE |
| 200404130A | Medicaid | IN | |
| 000000280934 | Other | IN | ANTHEM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 01056773A (Indiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Deaconess Hospital Inc | 9032021431 | 308 |
News Archive
Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.
Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders. The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e., neurturin or NRTN, intended to restore and preserve dying neurons.
"A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?" The New York Times reports.
A reduced dose of lidocaine may have advantages over a standard dose for detecting inadvertent intrathecal catheter placement during epidural anesthesia, but neither is wholly reliable, say researchers.
› Verified 9 days ago
| Entity Name | Deaconess Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427097443 PECOS PAC ID: 9032021431 Enrollment ID: O20040115000129 |
News Archive
Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.
Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders. The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e., neurturin or NRTN, intended to restore and preserve dying neurons.
"A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?" The New York Times reports.
A reduced dose of lidocaine may have advantages over a standard dose for detecting inadvertent intrathecal catheter placement during epidural anesthesia, but neither is wholly reliable, say researchers.
› Verified 9 days ago
| Entity Name | Daviess County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619154820 PECOS PAC ID: 1557271665 Enrollment ID: O20040412001435 |
News Archive
Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.
Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders. The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e., neurturin or NRTN, intended to restore and preserve dying neurons.
"A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?" The New York Times reports.
A reduced dose of lidocaine may have advantages over a standard dose for detecting inadvertent intrathecal catheter placement during epidural anesthesia, but neither is wholly reliable, say researchers.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tracy R Woodward, MD Po Box 78, Evansville, IN 47701-0078 Ph: (812) 303-0212 | Tracy R Woodward, MD 1133 Lincoln Ave 201, Evansville, IN 47714-1028 Ph: (812) 303-0212 |
News Archive
Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.
Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders. The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e., neurturin or NRTN, intended to restore and preserve dying neurons.
"A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?" The New York Times reports.
A reduced dose of lidocaine may have advantages over a standard dose for detecting inadvertent intrathecal catheter placement during epidural anesthesia, but neither is wholly reliable, say researchers.
› Verified 9 days ago
Mr. David Michael Holajter, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 415 Mulberry St, Evansville, IN 47713 Phone: 812-423-7791 Fax: 812-436-4316 | |
James M Boling, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 7200 E Indiana St, Evansville, IN 47715 Phone: 812-476-7200 Fax: 812-471-4514 | |
Henry B Kaplan, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3900 Washington Ave # 100, Evansville, IN 47714 Phone: 812-485-6694 | |
Mrs. Carla Maria Brandt, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1312 Professional Blvd Ste 201, Evansville, IN 47714 Phone: 812-476-7523 | |
Bhargav A Trivedi, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 600 Mary St, Evansville, IN 47710 Phone: 812-450-7338 Fax: 812-450-2193 | |
Dr. Roderick Lance Warren, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 801 Saint Marys Dr, Ste 303, Evansville, IN 47714 Phone: 812-477-1560 Fax: 812-477-1595 | |
John Robert Lorenz, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1101 Professional Blvd Ste 100, Evansville, IN 47714 Phone: 812-477-7246 |